Wall Street expects a year-over-year increase in earnings on higher revenues when Nuvation Bio Inc. (NUVB) reports results ...

Entera Bio Ltd. (ENTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric ...

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the ...

That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...

On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB), an estimated $2.93 million trade based on quarterly average pricing. Nuvation Bio is ...

Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...